Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203578 · ClinicalTrials.gov registry record · NA
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02203578 is a NA study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 1 participants.
The verdict
NCT02203578, a NA study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This pilot clinical trial studies romidepsin in treating patients with graft-versus-host disease (GVHD) that has not responded to treatment with steroids. Romidepsin may be an effective treatment for graft-versus-host disease caused by a bone marrow or stem cell transplant.
Interventions
- OTHER laboratory biomarker analysis
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-06-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02203578
The ClinicalTrials.gov registry entry for NCT02203578 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02203578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02203578 about?
NCT02203578 is a clinical study titled "Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease". This pilot clinical trial studies romidepsin in treating patients with graft-versus-host disease (GVHD) that has not responded to treatment with steroids. Romidepsin may be an effective treatment for graft-versus-host disease caused by a bone marrow or stem cell transplant.
What is the current status of trial NCT02203578?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2014-11. Estimated completion is 2016-06-14.
What interventions are being tested in trial NCT02203578?
The interventions under investigation include: laboratory biomarker analysis (OTHER), romidepsin (DRUG).
Who is sponsoring clinical trial NCT02203578?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.